HLS Therapeutics Inc
TSX:HLS

Watchlist Manager
HLS Therapeutics Inc Logo
HLS Therapeutics Inc
TSX:HLS
Watchlist
Price: 4.88 CAD -1.21% Market Closed
Market Cap: 154m CAD

Gross Margin
HLS Therapeutics Inc

83.1%
Current
89%
Average
47.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
83.1%
=
Gross Profit
47.1m
/
Revenue
56.8m

Gross Margin Across Competitors

HLS Therapeutics Inc
Glance View

Market Cap
154.9m CAD
Industry
Health Care

HLS Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The firm is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.

HLS Intrinsic Value
6.2 CAD
Undervaluation 21%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
83.1%
=
Gross Profit
47.1m
/
Revenue
56.8m
What is the Gross Margin of HLS Therapeutics Inc?

Based on HLS Therapeutics Inc's most recent financial statements, the company has Gross Margin of 83.1%.

Back to Top